Home›Stock Screener›TAKE›Fair Value

TAKE Fair Value

Average Fair Value
₹14.88
Current Market Price: ₹15.96
-6.77% Price Difference

TAKE (TAKE) average fair value is ₹14.88 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹15.96 (-6.77%), fair value range ₹0.37–₹60.24. Browse TAKE income statement for revenue, profit, balance sheet and cash flow data.

Fair Value Analysis Export

TAKE Fair Value vs Current Price — Valuation Summary

TAKE average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit TAKE share price screener.

Average Fair Value
₹14.88
Current Market Price
₹15.96
Price Difference
₹-1.08
Percentage Difference
-6.77%
Fair Value Range
₹0.37 - ₹60.24
Methods Used
8
Analysis based on 8 valuation methods: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF)

P/E Based Valuation

Current EPS ₹0.29
Sector Avg P/E 22.75
Historical Avg P/E N/A
Average Fair Value
₹5.58

P/B Based Valuation

Book Value/Share ₹20.67
Sector Avg P/B 4.33
Historical Avg P/B N/A
Average Fair Value
₹60.24

Price-to-Sales Valuation

Revenue/Share ₹3.61
Sector Avg P/S 4.0
Fair Value
₹14.46

Asset-Based Valuation

Book Value/Share ₹20.67
Liquidation Value/Share ₹16.8
Fair Value
₹20.67

Earnings Growth Model (PEG)

Current EPS ₹0.29
Growth Rate 5.32%
Fair P/E Ratio 5.32
Fair Value
₹1.54

Peter Lynch Fair Value

Current EPS ₹0.86
Growth Rate 5.32%
Dividend Yield 0%
Lynch Factor 5.32
Fair P/E Ratio 5.32
Data Source Quarterly Data (6 years)
Fair Value (Lynch Factor Adjusted)
₹4.57

Benjamin Graham Number

Current EPS ₹0.29
Book Value/Share ₹20.67
Graham Multiplier 22.5
Current P/E 19.45
Graham Criteria 0/3
Graham Number
₹11.61

Discounted Cash Flow (DCF)

Current FCF ₹9.0 Cr
FCF Growth Rate -59.45%
Discount Rate 10.0%
Terminal Growth 3.0%
Enterprise Value ₹6.12 Cr
DCF Fair Value
₹0.37

TAKE Fair Value Analysis — Data Sources & Coverage

TAKE financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Read TAKE dividend growth for the complete payout history and dividend yield track record.

Methods Used
8
Data Year
2026
Sector
Healthcare

Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.

Data Currency: Financial data is from the current year (2026).

TAKE vs Healthcare Sector Peers — P/E, P/B & Market Cap

TAKE P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.

Company Symbol P/E Ratio P/B Ratio Market Cap (₹ Cr)
Aurobindo Pharma AUROPHARMA 25.88 2.53 ₹96,652
Sat Kartar Life SATKARTAR 13.37 3.34 ₹226
Emcure Pharmaceuticals EMCURE 36.8 7.52 ₹37,799
Syngene International SYNGENE 69.95 3.2 ₹15,307
Divis Laboratories DIVISLAB 85.36 14.9 ₹247,470

Important Disclaimer

This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.

This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.

Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.